Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

All appraisals

1,189 appraisals, newest first, page 5 of 12
AppraisalMedicine pageNICE recommendationPublishedStatus
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations
NICE TA789
TepotinibRecommended18 May 2022Current
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy
NICE TA788
AvelumabOptimised11 May 2022Current
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
NICE TA787
VenetoclaxOptimised27 Apr 2022Current
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
NICE TA786
TucatinibRecommended27 Apr 2022Current
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)
NICE TA785
NivolumabTerminated (no company submission)20 Apr 2022Current
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
NICE TA784
NiraparibOptimised20 Apr 2022Current
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
NICE TA783
DaratumumabOptimised13 Apr 2022Current
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)
NICE TA782
TagraxofuspTerminated (no company submission)30 Mar 2022Current
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer
NICE TA781
SotorasibRecommended (Cancer Drugs Fund)30 Mar 2022Current
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
NICE TA780
NivolumabRecommended24 Mar 2022Current
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
NICE TA779
DostarlimabRecommended (Cancer Drugs Fund)16 Mar 2022Current
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria
NICE TA778
PegcetacoplanRecommended9 Mar 2022Current
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea
NICE TA777
SolriamfetolNot recommended9 Mar 2022Current
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea
NICE TA776
PitolisantNot recommended9 Mar 2022Current
Dapagliflozin for treating chronic kidney disease
NICE TA775
DapagliflozinOptimised9 Mar 2022Current
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)
NICE TA774
LenalidomideTerminated (no company submission)9 Mar 2022Current
Empagliflozin for treating chronic heart failure with reduced ejection fraction
NICE TA773
—Optimised9 Mar 2022Current
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies
NICE TA772
PembrolizumabRecommended23 Feb 2022Current
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)
NICE TA771
DaratumumabTerminated (no company submission)9 Feb 2022Current
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA770
PembrolizumabOptimised9 Feb 2022Current
Palforzia for treating peanut allergy in children and young people
NICE TA769
—Recommended2 Feb 2022Current
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA768
UpadacitinibOptimised2 Feb 2022Current
Ponesimod for treating relapsing–remitting multiple sclerosis
NICE TA767
PonesimodRecommended2 Feb 2022Current
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma
NICE TA766
PembrolizumabRecommended2 Feb 2022Current
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
NICE TA765
VenetoclaxRecommended2 Feb 2022Current
Fremanezumab for preventing migraine
NICE TA764
FremanezumabOptimised2 Feb 2022Current
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable
NICE TA763
DaratumumabRecommended2 Feb 2022Current
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal)
NICE TA762
OlaparibTerminated (no company submission)2 Feb 2022Replaced by TA1040
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
NICE TA761
OsimertinibOptimised (Cancer Drugs Fund)19 Jan 2022Current
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
NICE TA760
SelpercatinibRecommended (Cancer Drugs Fund)12 Jan 2022Current
Fostamatinib for treating refractory chronic immune thrombocytopenia
NICE TA759
FostamatinibNot recommended7 Jan 2022Replaced by TA835
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy
NICE TA758
SolriamfetolOptimised5 Jan 2022Current
Cabotegravir with rilpivirine for treating HIV-1
NICE TA757
CabotegravirRecommended5 Jan 2022Current
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
NICE TA756
FedratinibRecommended (Cancer Drugs Fund)16 Dec 2021Current
Risdiplam for treating spinal muscular atrophy
NICE TA755
RisdiplamOptimised16 Dec 2021
Updated 15 Dec 2023
Current
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome
NICE TA754
MogamulizumabOptimised15 Dec 2021Current
Cenobamate for treating focal onset seizures in epilepsy
NICE TA753
CenobamateOptimised15 Dec 2021
Updated 24 Jul 2025
Current
Belimumab for treating active autoantibody-positive systemic lupus erythematosus
NICE TA752
BelimumabOptimised15 Dec 2021Current
Dupilumab for treating severe asthma with type 2 inflammation
NICE TA751
DupilumabOptimised8 Dec 2021Current
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)
NICE TA750
OlaparibTerminated (no company submission)8 Dec 2021Current
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)
NICE TA749
LiraglutideTerminated (no company submission)1 Dec 2021Current
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
NICE TA748
MexiletineRecommended1 Dec 2021Current
Nintedanib for treating progressive fibrosing interstitial lung diseases
NICE TA747
NintedanibRecommended17 Nov 2021Current
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer
NICE TA746
NivolumabRecommended17 Nov 2021Current
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)
NICE TA745
—Terminated (no company submission)10 Nov 2021Current
Upadacitinib for treating moderate rheumatoid arthritis
NICE TA744
UpadacitinibOptimised10 Nov 2021Current
Crizanlizumab for preventing sickle cell crises in sickle cell disease
NICE TA743
CrizanlizumabOptimised3 Nov 2021Current
Selpercatinib for treating advanced thyroid cancer with RET alterations
NICE TA742
SelpercatinibRecommended (Cancer Drugs Fund)3 Nov 2021Replaced by TA1038
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
NICE TA741
ApalutamideOptimised28 Oct 2021Current
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer
NICE TA740
ApalutamideRecommended28 Oct 2021Current
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable
NICE TA739
AtezolizumabRecommended27 Oct 2021Current
Berotralstat for preventing recurrent attacks of hereditary angioedema
NICE TA738
BerotralstatOptimised20 Oct 2021Current
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
NICE TA737
PembrolizumabRecommended20 Oct 2021
Updated 29 Aug 2024
Current
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy
NICE TA736
NivolumabOptimised20 Oct 2021Current
Tofacitinib for treating juvenile idiopathic arthritis
NICE TA735
TofacitinibOptimised20 Oct 2021Current
Secukinumab for treating moderate to severe plaque psoriasis in children and young people
NICE TA734
SecukinumabRecommended7 Oct 2021Current
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
NICE TA733
InclisiranOptimised Only in research6 Oct 2021Current
Baloxavir marboxil for treating acute uncomplicated influenza in people 12 years and over (terminated appraisal)
NICE TA732
Baloxavir MarboxilTerminated (no company submission)6 Oct 2021Current
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)
NICE TA731
VericiguatTerminated (no company submission)29 Sep 2021Current
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)
NICE TA730
AvapritinibTerminated (no company submission)29 Sep 2021Current
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria
NICE TA729
—Optimised22 Sep 2021Current
Midostaurin for treating advanced systemic mastocytosis
NICE TA728
MidostaurinRecommended22 Sep 2021Current
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE TA727
IsatuximabTerminated (no company submission)22 Sep 2021Current
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE TA726
DaratumumabTerminated (no company submission)22 Sep 2021Current
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
NICE TA725
AbemaciclibRecommended15 Sep 2021Current
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer
NICE TA724
NivolumabNot recommended8 Sep 2021Current
Bimekizumab for treating moderate to severe plaque psoriasis
NICE TA723
BimekizumabRecommended1 Sep 2021Current
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
NICE TA722
PemigatinibRecommended25 Aug 2021Current
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
NICE TA721
Abiraterone acetateNot recommended18 Aug 2021Replaced by TA1110
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
NICE TA720
—Optimised18 Aug 2021Current
Secukinumab for treating active non-radiographic axial spondyloarthritis
NICE TA719
SecukinumabOptimised21 Jul 2021Current
Ixekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis
NICE TA718
IxekizumabOptimised21 Jul 2021Current
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)
NICE TA717
DuvelisibTerminated (no company submission)21 Jul 2021Current
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
NICE TA716
NivolumabRecommended28 Jul 2021Current
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
NICE TA715
Adalimumab, Etanercept, Infliximab, AbataceptOptimised Not recommended14 Jul 2021Current
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)
NICE TA714
DasatinibTerminated (no company submission)14 Jul 2021Current
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
NICE TA713
NivolumabOptimised7 Jul 2021Current
Enzalutamide for treating hormone-sensitive metastatic prostate cancer
NICE TA712
EnzalutamideRecommended7 Jul 2021Current
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA711
GuselkumabOptimised30 Jun 2021Current
Ravulizumab for treating atypical haemolytic uraemic syndrome
NICE TA710
RavulizumabRecommended23 Jun 2021Current
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
NICE TA709
PembrolizumabOptimised23 Jun 2021Current
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
NICE TA708
—Optimised23 Jun 2021Current
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
NICE TA707
NivolumabRecommended15 Jun 2021Current
Ozanimod for treating relapsing–remitting multiple sclerosis
NICE TA706
OzanimodNot recommended9 Jun 2021Current
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
NICE TA705
AtezolizumabRecommended2 Jun 2021Current
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
NICE TA704
Trastuzumab deruxtecanRecommended (Cancer Drugs Fund)26 May 2021Current
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)
NICE TA703
IbrutinibTerminated (no company submission)26 May 2021Current
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)
NICE TA702
IbrutinibTerminated (no company submission)26 May 2021Current
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)
NICE TA701
—Terminated (no company submission)19 May 2021Current
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)
NICE TA700
SelinexorTerminated (no company submission)19 May 2021Replaced by TA970
Ofatumumab for treating relapsing multiple sclerosis
NICE TA699
OfatumumabRecommended19 May 2021Current
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
NICE TA698
RavulizumabRecommended19 May 2021Current
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban
NICE TA697
—Optimised Only in research12 May 2021
Updated 15 Jan 2025
Current
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy
NICE TA696
—Not recommended12 May 2021Replaced by TA984
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
NICE TA695
CarfilzomibOptimised28 Apr 2021Current
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
NICE TA694
Bempedoic acidOptimised28 Apr 2021
Updated 24 Jun 2026
Current
Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer
NICE TA693
OlaparibOptimised (Cancer Drugs Fund)28 Apr 2021Replaced by TA946
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA692
PembrolizumabNot recommended28 Apr 2021Current
Avelumab for untreated metastatic Merkel cell carcinoma
NICE TA691
AvelumabRecommended21 Apr 2021Current
Teduglutide for treating short bowel syndrome (terminated appraisal)
NICE TA690
TeduglutideTerminated (no company submission)21 Apr 2021Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.